Randy Sweis to Tumor Microenvironment
This is a "connection" page, showing publications Randy Sweis has written about Tumor Microenvironment.
Connection Strength
1.720
-
The Tumor Microenvironment of Bladder Cancer. Adv Exp Med Biol. 2020; 1296:275-290.
Score: 0.530
-
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8.
Score: 0.412
-
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell Rep. 2024 May 28; 43(5):114141.
Score: 0.179
-
Methods to assess anticancer immune responses in orthotopic bladder carcinomas. Methods Enzymol. 2020; 635:127-137.
Score: 0.131
-
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 05 22; 7(1):131.
Score: 0.127
-
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res. 2018 09; 6(9):990-1000.
Score: 0.121
-
Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. Urol Oncol. 2016 12; 34(12):556-565.
Score: 0.107
-
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma. Invest New Drugs. 2024 Apr; 42(2):179-184.
Score: 0.044
-
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
Score: 0.039
-
WNT/ß-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019 May 15; 25(10):3074-3083.
Score: 0.031